News, Publications and Press Releases

A full list of news articles from the
International Aspirin Foundation

​Summaries documents from
International Aspirin Foundation


Professor Garret FitzGerald MD FRS, from the Institute for Translational Medicine and Therapeutics at the University of Philadelphia, has given some logical scientific guidance regarding the use of regular medication such as NSAIDS and ACE inhibitors during the COVID-19 pandemic.

For further information please see:
FitzGerald GA. Misguided drug advice for COVID-19. Science 2020 March 20th letters 10.1126/science.abb8034

The FDA [19th March 2020] and the EMA [18th March 2020] have released statements explaining that there is no current scientific evidence to connect NSAIDS with worsening COVID-19.  Both agencies continue to monitor the situation.  The full statements can be read below:

The National Institute for Health and Care excellence NICE have produced a rapid evidence summary regarding NSAIDS for people with or at risk of COVID-19:

COVID-19 rapid evidence summary: acute use of non- steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 NICE ES23 14/04/20

The Medicines & Healthcare products Regulatory Agency (MHRA) have produced guidance on ibuprofen and COVID-19:

Ibuprofen and coronavirus (COVID-19)

This Swedish study examines the role of low-dose aspirin (75mg or 160mg) in people with chronic viral hepatitis in reducing the risk of HCC and liver-related mortality without a significantly higher risk of gastrointestinal bleeding.

Tracey G. Simon, M.D., M.P.H., Ann-Sofi Duberg, M.D., Ph.D., Soo Aleman, M.D., Ph.D., Raymond T. Chung, M.D., Andrew T. Chan, M.D., M.P.H., and Jonas F. Ludvigsson, M.D., Ph.D.

At the 2019 International Aspirin Foundation Scientific Conference ‘Benefits and Risks of Antithrombotic Therapy for Cardiovascular Disease Prevention’, held in Rome, Italy, international experts sought to discuss and debate the optimal antithrombotic strategy for the secondary prevention of cardiovascular disease (CVD) and to seek agreement around dosing and target populations for aspirin use in primary disease prevention.

Join us for an intimate meeting with members of the International Aspirin Foundation’s Scientific Advisory Board when Professors Peter Rothwell (University of Oxford); Lina Badimon (Cardiovascular Research Centre Barcelona) and Michael Gaziano (Harvard University) will highlight the role of The Foundation and its' engagement with the scientific community, providing a critical forum for many leading aspirin researchers worldwide to share their views and debate trial data.  This is achieved through science awards; symposia and conferences.  Find out more about entry criteria and applying for our £20,000 Senior Science Award. 

Big data pioneer Richard Peto combined evidence of huge clinical trials from cancer to heart disease and showed that taking seriously the causes of the big killers saves lives.

Professor Daniel José Piňeiro joins the International Aspirin Foundation (IAF) as associate member for South America. In this capacity he will provide a link to information and research about aspirin in South America and will help the IAF achieve its international role.

Release date: April 2019

PHILADELPHIA — The American Association for Cancer Research (AACR) honored Andrew T. Chan, MD, MPH, with the 2019 AACR-Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research during the AACR Annual Meeting 2019 being held March 29-April 3 in Atlanta. 

The International Aspirin Foundation Scientific Conference 2019 will take place in Rome, Italy on 28th June and bring together worldwide experts to facilitate multidisciplinary debate on the risks and benefits of antithrombotic therapy.

Release date: March 2019

Aspirin may be over 100 years old, but it is still full of surprises and the latest one is it may have a role in the treatment of cancer; new research lead by Professor Peter Elwood has highlighted a possible role in people who already have the disease

Release date: February 2019

The International Aspirin Foundation’s meeting in Edinburgh stimulates intense international debate and discussion amongst leaders in aspirin basic and clinical research

The principle investigators from five recently completed major aspirin trials (ARRIVE1, ASCEND2, ASPREE3-5, AspECT6 and seAFOod7) met at the Royal Society of Edinburgh on the 20th September 2018 to share their interpretation of important new findings.

Release date: October 2018

Senior Science Award Winner 2018 Announced

At the Science Awards Conference in Edinburgh on 20th September 2018, the International Aspirin Foundation's Senior Science Award Winner 2018, Prof Paola Patrignani, receives award from Prof Peter Rothwell.

Release date: September 2018


Emerging Aspirin Investigator Award Winner 2018 Announced

At the Science Awards Conference in Edinburgh on 20th September 2018, the International Aspirin Foundation's Emerging Aspirin Investigator Award Winner 2018, Dr Steven Dehmer, receives award from Dr Andrew Chan.

Release date: September 2018


New Trial Data

Two of the three recently completed primary prevention trials of low-dose aspirin were presented at the European Society of Cardiology Congress in Munich and simultaneously published online on August 26th.1,2

Release date: August 2018

BBC Radio 4, Inside Health : Professor Peter Rothwell

If you are taking low dose aspirin, typically 75mg a day, to protect against heart attack or stroke and you haven't been weighted then there is a good chance you are on the wrong dose.


Release date: August 2018

BBC Radio 4, Inside Health : Sir John Burn and the genetics of cancer

Professor Sir John Burn, has made Newcastle on Tyne a centre for research on genetics and disease.  His research with families with a propensity to develop certain cancers has shown the benefits of taking aspirin as a prevention against the disease. 


Release date: February 2018

Emerging Aspirin Investigator Award 2018 by the International Aspirin Foundation

The International Aspirin Foundation is seeking appropriate potential recipients for the Emerging Aspirin Investigator Award 2018.  Open to junior scientists the candidates needs to produce a statement and submit it by 30 April 2018

Release date: February 2018

Aspirin celebrates 120 years of innovation – gain access to the lectures

World experts from the medical and scientific community met in Berlin to celebrate and explore the current understanding of aspirin’s multifaceted role in modern Medicine. Read the full press release to view the conference overview video and register your interest to watch the conference lectures.

Release date: December 2017

G.L. Pharma becomes a Supporter of the International Aspirin Foundation

The International Aspirin Foundation is delighted to announce that G.L. Pharma GmbH has joined its group of Supporters who are aligned with The Foundation’s aims of increasing awareness and medical research in aspirin.

Release date: December 2017

Professor Carlo Patrono presents the Emerging Investigator Science Award

The 2017 winner, Dr Linxin Li, was selected for her ground breaking prospective population-based cohort study in patients with a first transient ischaemic attack, ischaemic stroke, or myocardial infarction treated with antiplatelet drugs (mainly aspirin based, without routine PPI use) after the event in the Oxford Vascular Study.

Release date: October 2017

Professor Peter Rothwell hands Professor Carlo Patrono the Chair of the Aspirin Foundation Scientific Advisory Board

Professor Carlo Patrono is delighted to take on the role of Chair of the Scientific Advisory Board (SAB) at the International Aspirin Foundation.  Professor Patrono looks forward to further developing the Foundation as an instrument for a joint venture of the medical/scientific community and Industry in exploring aspirin’s role in disease prevention and treatment.

Release date: September 2017


The International Aspirin Foundation strengthens its Scientific Advisory Board and welcomes Dr John Chia

The International Aspirin Foundation is delighted and honoured to welcome Dr John WK Chia to its Scientific Advisory Board.  Dr Chia is active in clinical trial research; and has developed and/or led numerous clinical trial studies– including immune check-point inhibitors, cancer vaccines, adoptive T cell, and small molecule targets for cancer.

Release date: July 2017


The International Aspirin Foundation celebrates 120 years of aspirin innovation

Clinicians and scientists from across the globe will meet at Charité – Berlin Museum of Medical History, Berlin on September 14th 2017 to celebrate 120 years since the synthesis of acetylsalicylic acid. Aspirin maybe relatively old in pharmaceutical terms but research regarding its many exciting indications and its role in disease prevention is new and expanding. The International Aspirin Foundation is delighted to be able to bring together world leaders in aspirin research and facilitate an in depth discussion of the important role aspirin has in the prevention and treatment of disease.

Release date: May 2017

Scientific Advisory Board welcomes new member, Prof Lina Badimon

The International Aspirin Foundation is delighted and honoured to welcome Professor Lina Badimon to its Scientific Advisory Board.  Professor Badimon’s research activities focus on thrombosis and hemostasis, atherosclerosis, lipids and inflammation.

Professor Badimon is the Director of the Cardiovascular Research Center in Barcelona (CSIC‐ICCC) in the Hospital Santa Creu and San Pau, Director of the Cardiovascular Research Chair of the Autonomous University of Barcelona and Director of the UNESCO Chair in Biomedical Sciences Training and Research.

Release date: Feb 2017


The International Aspirin Foundation expands its reach to China and  welcomes Professor Ge to the Scientific Advisory Board

The International Aspirin Foundation is delighted and honoured to welcome Professor Junbo Ge to its Scientific Advisory Board.

Professor Ge is a member of Chinese Academy of Sciences, professor and doctoral supervisor and works as the director for Shanghai Institute of Cardiovascular Disease and the Center for Stem Cells and Tissue Engineering.

Release date: Sept 2016

BBC Radio 4, Inside Health with Dr Mark Porter - Full Episode

Podcast from BBC Radio 4 Inside Health Programme, first broadcast on 4 October 2016. Dr Mark Porter interviews the International Aspirin Foundation Chairman, Prof Peter Rothwell, on the subject of Mini-Strokes.

Winners of the 2016 Senior Science Award Announced

Three world-class professors, Nancy Cook, Michael Gaziano and Julie Buring, From Boston were today, 30th September 2016, announced as the winners of the 2016 International Apirin Foundation Senior Science Award for their wok on the two largest ever randomised trials of Aspirin. You can also read the announcement on the Harvard School of Public Health website (this opens in a new window)

Release date: Sept 2016

The Aspirin Summaries, Issue 1

This report provides a relatively concise and current overview of activity, which reflects the depth of expertise and knowledge of the members of the Scientific Advisory Board, from both geographical and scientific areas.

Release date: August 2016

The Lancet - Published Online

Rothwell PM, Algra A, Chen z, Diener HC, Norrving B and Mehta Z. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: tome-course analysis of randomised trials.

Release date: May 2016

DISCLAIMER (updated November 2016)

  • The information, views and opinions expressed on the International Aspirin Foundation website are not endorsed or approved by members of the Scientific Advisory Board unless otherwise stated
  • The Information section on the website is compiled using current published information at the time of writing and whilst every effort has been made to avoid errors, professional clinical judgement is required to interpret the information given. The information given is referenced clearly for further analysis as required
  • Every effort is made by the International Aspirin Foundation to see that no misleading or inaccurate data, statement or opinion appear on the website, the International Aspirin Foundation cannot be held responsible for any errors or for any consequences arising from the use of the information contained on the website
  • The International Aspirin Foundation, its associates and the Scientific Advisory Board accept no liability whatsoever for the consequences of any such inaccurate or misleading data, information, opinion or statement
  • Any information involving drug usage, should only be followed in conjunction with the drug manufacturer's own published literature in their own country
  • Medical sciences evolve on a continual basis and therefore independent verification of the website content should be made
  • The information, views, opinions and any other material provided on this website should not be relied upon as a substitute to professional medical advice in relation to any medical condition. The International Aspirin Foundation, its associates and The Scientific Advisory Board accept no liability whatsoever for any consequences arising from any reliance placed on such information, views, opinions and other materials in lieu of professional medical advice
  • The Aspirin Foundation activities are supported through a sponsorship of Bayer AG, Berlin, Germany. The sponsor does not have any influence over the operations of the International Aspirin Foundation activities.